Position of the Transparency Council – Forxiga (dapagliflozin)
At its meeting on 7 January 2025, the Transparency Council adopted position No. 2/2025 on the evaluation of the drug Forxiga (dapagliflozin) for the indication of chronic heart failure
At its meeting on 7 January 2025, the Transparency Council adopted position No. 2/2025 on the evaluation of the drug Forxiga (dapagliflozin) for the indication of chronic heart failure